Table 4

Change of appetite and cachexia status (as defined in Methods) and MC4R 103Ile allele carrier status
Patients with
 Total
N1 = 499
[N = 479]
 Cachexia
N = 105 (21.1)
[N = 100]
 No cachexia
N = 394 (78.9)
[N = 379]
 Heterozygotes for the 103Ile- allele
N = 24 (4.8)
[N = 22]
 Homozygotes for the Val103-allele
N = 475 (95.2)
[N = 457]
Loss of appetite:
 232 (46.5)
[223]
 71 (67.6)
[69]
 161 (40.9)
[154]
 9 (37.5)
[8]
 223 (46.9)
[215]
General, not further specified
 95 (19)
[91]
 37 (35.2)
[36]
 58 (14.7)
[55]
 4 (16.7)
[3]
 91 (19.1)
[88]
Prior to initiation of therapy
 22 (4.4)
[21]
 14 (13.3)
[14]
 8 (2.1)
[7]
 2 (8.3)
[2]
 20 (4.2)
[19]
During therapy
 115 (23.1)
[111]
 20 (19.1)
[19]
 95 (24.1)
[92]
 3 (12.5)
[3]
 112 (23.6)
[108]
Occurrence of both food craving and revulsion
 18 (3.6)
[18]
 2 (1.9)
[2]
 16 (4)
[16]
 1 (4.2)
[1]
 17 (3.6)
[17]
Increase of appetite/no change
 249 (49.9)
[238]
 32 (30.5)
[29]
 217 (55.1)
[209]
 14 (58.3)
[13]
 235 (49.5)
[225]

1N = 499 [479]: Of the 509 patients ten without information were excluded, because the patients did not give any information or could not remember their appetite.

Numbers in square brackets denote the number of patients without early leucaemic preliminary stages.

Numbers in parentheses denote the particular percentage.

Knoll et al. BMC Cancer 2008 8:85   doi:10.1186/1471-2407-8-85